Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review

Negar Shaterian, 1,2,3 Negin Shaterian, 4 Aref Ghanaatpisheh, 2,3 Farnaz Abbasi, 2,3 Sara Daniali, 2,3 Maryam Jalali Jahromi, 5,6 Mohammad Sadegh Sanie, 5,7 and Amir Abdoli 1

1 Zoonoses Research Center, Jahrom University of Medical Sciences, Jahrom, Iran
2 Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran
3 USERN Office, Jahrom University of Medical Sciences, Jahrom, Iran
4 School of Nursing & Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran
6 Department of Internal Medicine, Jahrom University of Medical Sciences, Jahrom, Iran
7 Department of Anesthesia and Intensive Care, Jahrom University of Medical Sciences, Jahrom, Iran

Correspondence should be addressed to Mohammad Sadegh Sanie; m.sadeghsanie@gmail.com and Amir Abdoli; a.abdoli@jums.ac.ir

Received 29 November 2021; Revised 17 February 2022; Accepted 21 February 2022; Published 31 March 2022

Academic Editor: Marina De Tommaso

Copyright © 2022 Negar Shaterian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Migraine is one of the most common types of headache, and it is the second most common cause of neurological disorders, with an annual prevalence of about 15% of the population. This study aimed to evaluate the effect of BoNT-A on the duration and intensity of migraine attacks. In addition, we investigated the effective injection sites.

Methods. According to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines, we searched online databases, including Web of Science, PubMed, EMBASE, Scopus, Cochrane Library, ProQuest, ClinicalTrials.gov, and Google Scholar from 2011 to 2021. A total of 24 articles were included in the study. The use of BoNT-A in individuals suffering from chronic migraine (CM) decreases the frequency of migraine attacks per month, pain intensity, medication use, emergency visits, and migraine-related disabilities. The BoNT-A was well tolerated and leads to improved performance and better quality of life (QoL). Overall, treatment with BoNT-A in adults with CM is beneficial. In addition, the use of BoNT-A in individuals with vestibular migraine (VM) reduces the frequency of migraines and brings about the improvement of disability status caused by migraine headaches. Meanwhile, the use of BoNT-A reduces the frequency of migraine attacks per month among individuals with chronic refractory migraine (CRM). Conclusions. The use of BoNT-A is a low-cost option for the treatment of various kinds of migraines, including chronic, episodic, unilateral, and vestibular types. BoNT-A can reduce the frequency of migraine attacks per month and diminish the severity of pain.

1. Introduction

Migraine is a type of primary headache disorder, and it is the second most common cause of neurological disorders after tension headache with an annual prevalence of about 15% of the population. According to studies conducted in Iran, about 14% of the population was suffering from the disorder in 2016 [1, 2]. Individuals suffering from migraines may have a variety of problems, such as sickness absence and reduced productivity at work, school, and home. Hence, the disease imposes a heavy burden on society [3]. Migraine, as a disease with a genetic background, has a controversial pathogenesis due to the diversity of factors affecting it. In this regard, specific factors such as genes, cytokines (interleukin 1 beta (IL-1B), IL-6, and tumor necrosis factor α (TNFa)), immune cells (mast cells), and environmental features play an important role. Therefore, there are several treatment options targeting each of the above factors [4–6].
Nowadays, a variety of clinical medications, including β-blockers, antiepileptic drugs, calcium antagonists, antidepressants, calcitonin gene-related peptide (CGRP), and onabotulinumtoxinA (BoNT-A), are utilized to prevent migraine [7, 8].

BoNT-A is a complex protein produced by a Gram-positive and anaerobic bacterium called Clostridium botulinum [9]. Initially, it was hypothesized that the mechanism of pain relief by this toxin is due to muscle relaxation and subsequent hypotension [10]. Several mechanisms have been proposed regarding the function of BoNT-A, including inhibiting the exocytosis of neurochemicals and proteins of the motor and sensory systems, reducing exocytosis of proinflammatory cells, neurotransmitters, and excitatory neuropeptides of the nervous system such as substance P, CGRP, glutamate, and inhibiting soluble N-ethylmaleimidesensitive factor attachment protein receptors (SNARE) [11]. Recent experimental studies have shown that BoNT-A may influence the central nervous system (CNS). The toxin was initially used to treat dystonia and blepharospasm, but following two controlled clinical trials, it was later approved that BoNT-A can also prevent migraine [12]. In these studies, known as the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT), it was found that BoNT-A injection, compared with placebo, affected the frequency and severity of chronic migraine (CM) and alleviated symptoms. The most common side effects observed after the injection included neck pain, muscle weakness, and pain in the injection site. Repeating this treatment showed that the use of BoNT-A was safe and well tolerated [13].

The practical guidelines for the use of BoNT-A in the treatment of CM, presented by the European Headache Federation (EHF), recommended that 155–195 units should be repeated in the form of intramuscular injection in 31–39 areas around the head and neck at 12-week intervals. Patients should preferably try some other strategies for preventing migraine before starting treatment with BoNT-A [14]. On the other hand, the cost-effectiveness of BoNT-A treatment is an important factor for both the individual and the community. According to the calculations of the National Institute for Health and Care Excellence (NICE), using this method is cost-effective [15]. Since the prevalence of migraine is relatively high and it is associated with disability, this systematic review aimed to evaluate the effect of BoNT-A on migraine attacks. In addition, we investigated the effective injection sites for BoNT-A on migraine attacks.

2. Materials and Methods

2.1. Search Strategy. The PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) guideline has been used to design the study [16]. The databases of Web of Science, PubMed, EMBASE, Scopus, Cochrane Library, ProQuest, ClinicalTrials.gov, and Google Scholar were systematically searched for relevant studies published between 2011 and the end of 2021. Before 2011, there are some systematic reviews about this topic [17], so we have performed updated systematic reviews. We searched according to MeSH: Migraine (text word) OR Migraines (MeSH term) OR Disorder, Migraine (MeSH term) OR Disorders, Migraine (MeSH term) OR Migraine Disorder (MeSH term) OR Migraine Headache (MeSH term) OR Headache, Migraine (MeSH term) OR Headaches, Migraine (MeSH term) OR Migraine Headaches (MeSH term) AND OnabotulinumtoxinA (text word) OR Clostridium botulinum A Toxin (MeSH term) OR Botulinum Toxin A (MeSH term) OR Botulinum A Toxin (MeSH term) OR Botulinum Neurotoxin A (MeSH term) OR Neurotoxin A, Botulinum (MeSH term) OR Botulinum A Toxin (MeSH term) OR Toxin, Botulinum A (MeSH term) OR Botulinum Toxin Type A (MeSH term) OR Botulinum Neurotoxin Type A (MeSH term) OR Clostridium Botulinum Toxin Type A (MeSH term) OR Botox (MeSH term) OR OnabotulinumtoxinA (MeSH term).

2.2. Inclusion and Exclusion Criteria. The clinical trial studies conducted between 2011 and 2021 were included in this review without any language restrictions. Nonoriginal articles, including letters, comments, observational studies, and case reports, were excluded. If the language used in an article was other than English or Persian, we asked a translator to translate the article.

2.3. Types of Participants. The studies were selected if their participants were people with acute migraine, people 12 years old or older, and people with no systemic disorders.

2.4. Types of Interventions. The studies were reviewed if they used BoNT-A for migraine treatment.

2.5. Types of Outcome Measures. All included studies were on the number of days with migraine headaches.

2.6. Data Extraction. Eligible articles were initially screened by title and abstract. All selected articles were imported into the EndNote X8 software (Thomson Reuters, New York, USA), and duplicated articles were checked and then removed. After removing duplicates, the full text of the qualified records was retrieved and two expert investigators (two first authors, NSH and NSH) evaluated the eligibility of the articles. Afterward, an investigator (AG) extracted the required information, and two others (FA and SD) rechecked them; any discrepancy of opinion or disagreement was resolved by consensus and discussion with the lead investigator (AA) [18]. Data are collected in Table 1.

3. Results

Our search strategy resulted in the retrieval of a total of 845 articles, of which 24 studies were included in the study. In the first phase, 602 duplicate articles were excluded from the study. Subsequently, 174 nonclinical trial studies and unrelated studies according to the title and abstracts of articles were excluded from the study. Next, the full text of 69 articles was reviewed and 45 articles were excluded. Finally, 24 high-quality articles evaluating the effect of BoNT-A in the
| No | Reference | Study type | Location | Sample size | Age | Migraine days/month | Migraine type | Botox dose (unit) | The site of Botox injection | The outcome of using Botox |
|----|------------|------------|----------|-------------|-----|---------------------|--------------|------------------|-----------------------------|----------------------------|
| 1  | Görür et al. [37] | CT1 | Turkey | 60 | 45.86 | NR2 | Vestibular | 155 | Corrugator 10 units/2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervicalparaspinalis 20 units/4 points; trapezium 30 units/6 points, (PREEMPT™) | Decreased attack frequency in vestibular migraine patients and improvement in the migraine disability assessment score |
| 2  | Alshalah et al. [40] | CT | Iraq | 100 | NR | 20 | NR | 155-195 | 7 specific muscles in the head and neck in 6 zones: 1. forehead. 2. The back of the head. 3. Temples. 4. The upper back, behind the shoulder blades. 5. Neck. 6. Nose bridge | Decrease in headache-day frequency |
| 3  | Akçay [36] | CT | Turkey | 53 | ≥ 15 | Chronic | Group 1 | 68 | Bilateral to frontal muscles, temporal muscles, occipital muscles, semispinalis capitis, splenius capitis, and trapezius muscles in the cervical region | Decreasing headache-day frequency and the severity of pain treatment in both young and old population |
| 4  | Ahmed et al. [20] | CT | Germany, Italy, Norway, Russia, Sweden, Spain, and UK | 641 | 45.4 | 20.6 | Chronic | 155 | Corrugator 10 units/2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervicalparaspinalis 20 units/4 points; trapezium 30 units/6 points, (PREEMPT™) | Reduction in headache-day frequency |
| No | Reference              | Study type | Location  | Sample size | Age   | Migraine days/month | Migraine type | Botox dose (unit) | The site of Botox injection                                                                 | The outcome of using Botox injection                                                                 |
|----|------------------------|------------|-----------|-------------|-------|---------------------|---------------|------------------|--------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| 5  | Tang et al. [21]       | RCT        | Brazil    | 18          | 42    | 28                  | Chronic       | 155              | Corrugator 10 units/2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezium 30 units/6 points, (PREEMPT) | A sharp decrease during the treatment and post-treatment phases, compared with baseline                                                             |
| 6  | Grazzi [22]            | CT         | Italy     | 50          | 51.2  | 25.3                | Chronic       | 155              | Corrugator 10 units/2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezium 30 units/6 points, (PREEMPT) | Significant decrease in headache-day frequency and medication intake per month                                                                   |
| 7  | Demiryurek et al. [23] | CT         | Turkey    | 60          | 34.73 | 18.78               | Chronic       | 155              | Corrugator 10 units/2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezium 30 units/6 points, (PREEMPT) | Decreased headache days in 88.3 % of patients                                                  |
| No | Reference         | Study type | Location  | Sample size | Age | Migraine days/month | Migraine type | Botox dose (unit) | The site of Botox injection | The outcome of using Botox                                                                 |
|----|-------------------|------------|-----------|-------------|-----|----------------------|---------------|------------------|-----------------------|------------------------------------------------------------------------------------------|
| 8  | Lipton et al. [24] | RCT        | USA       | 1236        | 41  | O/O (onabotulinumtoxinA/ onabotulinumtoxinA) | 19.9          |                  | Corrugator 10 units/ 2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezium 30 units/6 points, (PREEMPT) | -Significant reduction in Headache Impact Test (HIT-6) and Migraine-Specific Quality of Life Questionnaire (MSQ) for onabotulinumtoxinA versus placebo, in the double-blind (DB) phase. -Significant reduction in HIT-6 for onabotulinumtoxinA/ onabotulinumtoxinA (O/O) versus placebo/ onabotulinumtoxinA (P/O), in the open-label (OL) phase. -Improvement in health-related quality of life (HRQoL) in three MSQ domains |
| 9  | Vikelis [25]      | CT         | Greece    | 119         | 21-75 | NR                   | Chronic       | 155 and 40 for additional dose | Corrugator 10 units/ 2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezium 30 units/6 points, (PREEMPT) | The use of onabotulinumtoxinA for the prophylaxis of chronic migraine, as this intervention proved effective, safe, and well tolerated |
| 10 | Ahmed et al. [26] | CT         | UK        | 465         | 47.5 | ≥15                  | Chronic       | 155              | Corrugator 10 units/ 2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezium 30 units/6 points, (PREEMPT) | Reduction in headache-day frequency |
| No | Reference      | Study type | Location            | Sample size | Age  | Migraine days/month | Migraine type | Botox dose (unit) | The site of Botox injection | The outcome of using Botox injection |
|----|----------------|------------|---------------------|-------------|------|--------------------|---------------|------------------|-----------------------------|----------------------------------|
| 11 | Boudreau et al. [27] | CT         | Canada and USA      | 32          | ≥ 18 | 16.8 (p < 0.0001)  | Chronic       | 155              | Corrugator 10 units/ 2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezium 30 units/6 points, (PREEMPT) | Reductions in headache-day frequency |
| 12 | Hou, M [39] RCT | China      | 102                 | >18         | NR   | Chronic and episodic | -2.5 U each site -25 U per subject | Fixed sites (n = 41) including occipitofrontalis, corrugator supercili, temporalis, and trapezium, or at acupoint sites (n = 42) including Yintang (EX-HN3), Taiyang (EX-HN5), Baihui (GV20), Shuaigu (GB8), Fengchi (GB20) and Tianzhu (BL10) | Because of more efficient improvement for reducing migraine frequency, density, duration, and associated symptoms in acupoint sites group than in fixed sites groups, the efficacious site for migraine treatment is acupoint sites |
| 13 | Cady et al. [28] RCT | USA       | 20                  | 48.5        | NR   | Chronic            | 155           | Corrugator 10 units/ 2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezium 30 units/6 points, (PREEMPT) | ≥50% reduction in headache-day frequency |
| No | Reference                  | Study type | Location           | Sample size | Age   | Migraine days/month | Migraine type | Botox dose (unit) | The site of Botox injection                                                                 | The outcome of using Botox                                                                 |
|----|----------------------------|------------|--------------------|-------------|-------|---------------------|---------------|------------------|--------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| 14 | Cernuda-Morollón et al. [29]| CT         | Spain              | 132         | 46.3  | NR                  | Chronic       | 155-195           | Corrugator 10 units/2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezium 30 units/6 points, (PREEMPT) | Decrease in consumption of any acute medication and emergency visits (long-term response to onabotA) |
| 15 | Holland [30]               | RCT        | Brazil             | 58          | 18-85 | NR                  | Chronic       | 100              | Frontal 3U/2-4 points, temporal 3U/2-4 points, occipital 3U/2-4 points                          | No significant differences between active intervention or placebo groups                  |
| 16 | Aurora et al. [31]         | RCT        | North America and Europe | 1384       | 18-65 | ≥15                 | Chronic       | NR               | Corrugator 10 units/2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezium 30 units/6 points, (PREEMPT) | Significantly reduce headache-related disability and improve functioning                   |
| 17 | Cady et al. [32]           | RCT        | USA                | 59          | 36.9  | 11.9                | Chronic       | Up to 200        | NR                                                           | At least a 50% reduction in headache-day frequency in subjects with chronic migraine         |
| 18 | Chankrachang et al. [33]   | RCT        | Thailand           | 128         | 18-65 | NR                  | Chronic       | 120 240          | 2 subcutaneous injections into both the frontal and temporal regions of the face, and 2 intramuscular injections into the occipital region | Efficacy and tolerability of Dysport as a migraine treatment in particularly 240 U dose |
| No | Reference | Study type | Location | Sample size | Age | Migraine days/month | Migraine type | Botox dose (unit) | The site of Botox injection | The outcome of using Botox injection |
|----|------------|------------|----------|-------------|-----|---------------------|--------------|-----------------|-----------------------------|-----------------------------------|
| 19 | Lipton [34] | RCT | USA | 1384 | 41.3 | NR | Chronic | 155 | corrugator 10 units/2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezius 30 units/6 points, (PREEMPT) | Meaningful reductions in headache impact and improvements in health-related quality of life (HRQoL) |
| 20 | Oterino [38] | CT | Spain | 35 | 24-68 | 24.7 | Chronic refractory | First: 100 U Second: 200 U | One site into corrugator, two into frontalis, three into temporalis, two into suboccipitalis, one into semispinalis and one into splenius/5 units per site | Decrease in headache days per month-18% of patients experienced adverse effects |
| 21 | Aurora et al. [35] | RCT | Canada, Croatia, Germany, Switzerland, UK, and USA | 1384 | 18-65 | ≥ 15 | Chronic | 155 | Corrugator 10 units/2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezius 30 units/6 points, (PREEMPT) | Safety and efficacy in adults with chronic migraine |
| 22 | Winner et al. [19] | RCT | USA | 115 | 12 to <18 years | ≥15 | Chronic | 155, 74 | Corrugator 10 units/2 points; procerus 5 units/1 point; frontalis 20 units/4 points; temporalis 40 units/8 points; occipital 30 units/6 points; cervical paraspinalis 20 units/4 points; trapezius 30 units/6 points, (PREEMPT) | OnabotulinumtoxinA was well tolerated in this adolescent population. In adults, the beneficial effects of onabotulinumtoxinA have been shown to increase with multiple treatments. The most reported adverse events were neck pain, upper respiratory tract infection, migraine, and nasopharyngitis |
Table 1: Continued.

| No | Reference       | Study type | Location | Sample size | Age       | Migraine days/month | Migraine type | Botox dose (unit) | The site of Botox injection | The outcome of using Botox                                                                 |
|----|-----------------|------------|----------|-------------|-----------|---------------------|---------------|------------------|-----------------------------|------------------------------------------------------------------------------------------|
| 23 | Shah et al. [41]| RCT        | USA      | 10          | 8-17      | 15.5 to 4 days/month| Chronic       | A median dose of 165 total units was used per treatment |

- Median pretreatment to post-treatment headache frequency was 15.5 to 4 days/month ($p < 0.0001$), durations were 8 [0, 24] to 1 [0, 7] hours ($p < 0.025$), and intensity was 6 [4, 8] to 4 [2, 5] ($p < 0.0063$). Patients had no serious adverse events.

| 24 | Shah et al. [42]| RCT        | USA      | 15          | 8 to 17 years old | Chronic migraines (at least 6 months), and 15 or more headache days in a 4-week baseline period | Chronic | 155 units at 31 injection sites—in 3-month intervals and follow-up visits every 6 weeks |

- Treatment resulted in a statistically significant decrease from the baseline values compared with placebo: frequency (20 (7 to 17) vs 28 (23 to 28); $p = 0.038$), intensity (5 (3 to 7) vs 7 (5 to 9); $p = 0.047$), and PedMIDAS (Pediatric Migraine Disability Score) (3 (2 to 4) vs 4 (4 to 4); $p = 0.047$). There was no statistically significant difference in the duration (10 (2 to 24) vs 24 (4 to 24); $p = 0.148$) of migraines between the two groups.

CT: controlled trial, NR: not reported, RCT: randomized controlled trial, PREEMPT: Phase III Research Evaluating Migraine Prophylaxis Therapy.
treatment of migraine from 2011 to the end of 2021 were included (Figure 1 and Table 1). Figure 1 shows the article selection process according to the PRISMA protocol.

The countries in which the articles had been published were as follows: the United States (n = 9), Turkey (n = 3), the United Kingdom (n = 3), Spain (n = 3), Germany (n = 2), Italy (n = 2), Brazil (n = 2), Canada (n = 2), Russia (n = 1), Iraq (n = 1), Greece (n = 1), China (n = 1), North America (n = 1), Europe (n = 1), Thailand (n = 1), Switzerland (n = 1), Norway (n = 1), Sweden (n = 1), and Croatia (n = 1).

Most (79.16%) studies evaluated the effect of BoNT-A on CM [19–36]. One study examined the effect of BoNT-A on vestibular migraine (VM) [37], one study evaluated chronic refractory migraine (CRM) [38], and one study examined chronic and episodic migraine (EM) [39]. Moreover, one study did not mention the type of migraine [40]. The minimum and maximum ages of the participants were 12 and 86 years, respectively. Additionally, the lowest and highest numbers of migraine attacks per month were reported as 11 and 20 days, respectively. The doses of Botox used varied in different studies (from 2.5 to 200 units), but most studies (58.3%) used 155 units of Botox. Indeed, one study did not mention the dosage [31].

In the 15 articles of PREEMPT [19–29, 31, 34, 35, 37], the sites of BoNT-A injection were as follows: two sites in the corrugator, one site in the procerus, six sites in the occipital, eight sites in the temporalis, four sites in the frontalis, six sites in the trapezius, and four sites in the cervical paraspinals. In other articles [30, 33, 36, 38–40], the sites of BoNT-A injection were different, which included the forehead, the back of the head, temples, upper back, behind the shoulder blades, neck, nose bridge, bilaterally to frontalis muscles, temporal muscles, occipital muscles, semispinalis capitis, splenius capitis, trapezius muscles in the cervical region, occipitofrontalis corrugator supercilii, and acupoint sites.

According to 11 studies [20–24, 26–29, 31, 32, 34, 36], BoNT-A reduced the frequency of CM among patients. Meanwhile, one study found that the same is true for CRM. In addition, three studies [24, 34, 36] showed that BoNT-A reduced pain intensity in patients suffering from CM. Furthermore, one study [30] demonstrated that the use of BoNT-A had no significant effect on CM. However, three studies [19, 25, 33] claimed that BoNT-A is well tolerated in patients with CM. Findings from two studies [22, 29] showed that the use of BoNT-A in CM treatment led to reduced use of other drugs. In addition, one study [29] found that using BoNT-A reduced emergency visits. Findings from two studies [24, 34] showed that treatment with BoNT-A in individuals with CM improves health-related quality of life (QoL). In addition, one study [37] found that BoNT-A reduced the incidence of VM and improved the function; this was also reported in a study on CM. Meanwhile, another study proved that the use of BoNT-A was generally effective in adults suffering from CM. Three studies used BoNT-A for the pediatric and adolescent population [19, 41, 42], in which treatment resulted in reduced frequency of headache, duration of migraine, and pain intensity.

4. Discussion

The results of this study showed that Botox is an option with high potential for treating migraine as an inflammatory neurological disease. However, taking advantage of BoNT-A in individuals suffering from CM reduces the frequency of migraine attacks per month, the severity of pain, use of other drugs, emergency visits, and disabilities associated with migraine headaches. Furthermore, BoNT-A is well tolerated and leads to improved performance and health-related QoL. Generally, treatment with BoNT-A in adults with CM is beneficial. In addition, the use of BoNT-A in individuals with VM reduces the frequency of migraine attacks per month and improves the disability status caused by migraine headaches. Moreover, the use of BoNT-A decreases the frequency of migraine attacks per month among those suffering from CRM. Apart from Botox, there are other treatment options. However, considering the availability and cost-effectiveness, Botox is assumed a novel and cost-effective option for these patients.

The effectiveness of BoNT-A has been studied from various perspectives and by different groups [43–45]. Mihm et al. evaluated the safety and efficacy of BoNT-A toxin in the prophylactic treatment of adults with CM compared with placebo. They reported that BoNT-A treatment is well tolerated in adults with CM, and it can be considered as a safe method in this regard. However, BoNT-A is associated with an increased risk of side effects, and there is still uncertainty about the effectiveness of BoNT-A in comparison with placebo [46]. A systematic review and meta-analysis by Herd et al. evaluated the effect of botulinum toxin on migraine prevention among adults, and the results showed that botulinum toxin treatment alleviated the severity of CM and EM. Besides, in CM, botulinum toxin reduced the migraine frequency by two days a month and had an acceptable safety profile. However, excessive use of migraine medications does not prevent the effectiveness of botulinum toxin. There is also no evidence to support or rule out the effectiveness of the toxin in EM. In addition, the relative risk of side effects associated with botulinum toxin treatment was measured as twice higher than placebo; however, considering comparison standards, it had a lower risk and withdrawal rate (3%) [47].

Another systematic review by Shen et al. investigated the effect of botulinum toxin A on the prevention of adult migraine disorders. By analyzing CM and EM, it was proved that BoNT-A did not decrease the frequency of migraine attacks per month compared with placebo. In addition, the analysis of the migraine disability assessment questionnaire reported by the patients showed that BoNT-A led to a significant improvement. Besides, this study showed that BoNT-A, as a treatment regimen, cured CM after 16 weeks of treatment, although this was not the case for EM [48].

In line with our study, Loebl et al. conducted a randomized controlled trial (RCT) to evaluate CM patients treated with botulinum toxin A (BT-A). After comparing BT-A with low-level laser therapy (LLLT), it was shown that both treatments reduced the frequency of headaches, acute drug use, and pain intensity. Anxiety decreased in the BT-A group, while sleep disorders were lessen in the LLLT
The results showed that both treatments could be used to treat CM without significant differences [49]. A study by Cheng and Ahmed showed that BoNT-A is a very good option for migraine prophylaxis in adults. In addition, it could be more effective when used in combination with other oral medications, and the low side effects of Botox could be controlled by adjusting the duration of treatment [50]. Moreover, in a prospective, real-life analysis by Ahmed et al. positive data from long-term treatment and follow-up of at least two years of patients with CM showed that they still appropriately responded even after two years. Additionally, it has been observed that CM subsequently changed into EM in some patients [51]. A systematic review by Argyriou et al. showed some conflicting results about the effectiveness of BoNT-A in primary headaches (PHs) other than CM. However, BoNTA may be a treatment option for patients who do not respond to common migraine prophylaxis. Based on the available limited evidence, BoNTA may be used for refractory tension headaches, trigeminal autonomic cephalgia, primary headaches, nummular headache, hypnic headache, and daily persistent headache. In this regard, the initial nature of cephalalgia and other unsuccessful medications should be considered. Therefore, experienced BoNTA therapy physicians are required to guide the treatment protocol for each patient to optimize good and safe outcomes [52].

Consistent with our study, in a clinical trial, Naderinabi et al. randomly divided 150 eligible patients into different groups of receiving acupuncture (A), botulinum toxin A (B), and control (C). During the 3-month study, pain intensity...
significantly decreased in all three groups, with a further decrease in group A. Frequency of migraine attacks per month, sickness absence, and the need for medication were evaluated three times among the participants of all groups. It was proved that all mentioned problems were significantly decreased and fewer side effects were seen in group A [53].

A meta-analysis by Affatato et al. [54] evaluated the effectiveness of onabotulinumtoxinA treatment in migraine patients with depression. They included eight studies for meta-analysis. Consequently, it was shown that onabotulinumtoxinA treatment significantly reduced the severity of CM and major depressive disorder in patients simultaneously suffering from both. Comparative analysis showed a strong equivalent effect in monomorbid and comorbid patients, with beneficial and specialized effects for some migraine characteristics [54]. Migraine during pregnancy is a widespread issue. According to some studies, migraine during pregnancy can increase the risk of maternal stroke and hypertensive disorders [55]. Therefore, finding a safe treatment option for this group of patients is essential. In a study by Wong et al., the effect of BoNT-A on 45 pregnant patients with CM was evaluated. Although the sample size of the study was small, the findings showed that BoNT-A had no adverse effects on pregnancy and birth [56]. However, children born from mothers diagnosed with migraine and treated with BoNT-A need to be followed up.

Schoenbrunner et al. [57] compared the cost-effectiveness of long-term botulinum toxin type A with surgical deactivation of trigger sites for the treatment of migraine headaches. In this study, the Markov model was developed, and the costs, utility, and other inputs of the model were determined from other studies. According to this model, surgical deactivation of trigger sites is a more cost-effective option for refractory migraine headaches. The model showed that surgical deactivation of trigger sites is more effective and less costly than long-term and targeted botulinum toxin type A over a patient’s lifetime [57]. This study is inconsistent with our findings because this study showed that due to the reduction in the use of other medications and emergency visits, treatment costs are reduced, and hence, this method is cost-effective. On the other hand, since Schoenbrunner et al. [57] compared the cost of treatment with another type of treatment (deactivation) that was not examined in our study, this inconsistency is justifiable. The results of this study will help clinicians to enhance their knowledge about which type of migraine could be treated by Botox, which is the best place for Botox injection, and what is the appropriate dose for each type of migraine.

Previous systematic reviews performed their analysis on adults [47, 48], but we did not have an age restriction. In this regard, three studies used BoNT-A for the pediatric and adolescent populations [19, 41, 42]. A study conducted by Shah et al. on children with migraine showed that patients with CM aged between 8 and 17 years who received BoNT-A experienced lower frequency and severity of migraine attacks than those receiving placebo [42]. On the other hand, in a 5-year retrospective longitudinal study, Shah et al. examined pediatric patients who were treated with BoNT-A because of their CM pain in an outpatient clinic [41]. After treatment, it was observed that the frequency of headaches, duration of migraine, and pain intensity were reduced. Besides, no serious side effects were reported [41]. Winner et al. [19] used Botox for the prevention of headaches in adolescents (12 to 18 years) with chronic migraine. They found that Botox was well tolerated in adolescents, and the treatment led to a reduced frequency of severe headache days [19].

4.1. Strengths and Limitations of This Study. One of the strengths of our work is the precise descriptive table that inserted the details of each included study. Furthermore, we did not have an age restriction for including the study.

Similar to other studies, our research had some limitations. There is a significant level of heterogeneity among studies for patients’ age, sample size, location, type of migraine, duration of migraine (days/month), Botox doses, unit of Botox dose, and site of Botox injection. Hence, due to the high heterogeneity among the studies, we could not perform a meta-analysis. Lack of online registration (PROSPERO) was another limitation to this study, because the data were already extracted (we pre-extracted the data and were unable to register it according to PROSPERO). However, there were no similar studies in the PROSPERO database since the search was performed.

5. Conclusions

In general, it can be noted that the use of BoNT-A, which is a type of Botox to treat migraines, is an effective and cost-effective option for the treatment of migraine. On the one hand, migraine disrupts QoL and can cause disability. BoNT-A treatment has effective benefits such as reducing the frequency and severity of headaches, improving disability status, and positively influencing health-related QoL. Furthermore, BoNT-A treatment reduces the use of other medications and emergency visits, both of which make BoNT-A treatment more cost-effective. No side effects other than neck pain have been reported following BoNT-A injection for several days. Further studies are recommended to determine whether treatment with BoNT-A has long-term side effects and whether it can be used as a treatment option if there are some underlying diseases. In addition, future studies may investigate the safety of using BoNT-A in pregnancy without causing complications for the mother and fetus.

Data Availability

All the data are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.
Authors’ Contributions

NSH, NSH, and AA conceived the study and critically analyzed the data. NSH, NSH, FA, MSS, MJJ, and AA interpreted the data. NSH, AGH, and SD drafted the manuscript. AA approved the final version of the paper. Negar Shaterian and Negin Shaterian equally contributed as the first author.

Acknowledgments

The authors would like to thank the Clinical Research Development Unit of Peymanieh Educational and Research and Therapeutic Center of the Jahrom University of Medical Sciences for supporting this work.

Supplementary Materials

The PRISMA checklist for reporting systematic reviews.

References

[1] L. R. Øie, T. Kurth, S. Gulati, and D. W. Dodick, “Migraine and risk of stroke,” Journal of Neurology Neurosurgery and Psychiatry, vol. 91, no. 6, pp. 593–604, 2020.
[2] Z. Farhadi, S. Alidoost, M. Behzadifar et al., “The prevalence of migraine in Iran: a systematic review and meta-analysis,” Iranian Red Crescent Medical Journal, vol. 18, no. 10, Article ID e40061, 2016.
[3] K. M. Kim, S.-J. Cho, H. J. Shin et al., “Prevalence, disability, and management patterns of migraine in Korea: nationwide survey data from 2009 and 2018,” Journal of Clinical Neurology, vol. 17, no. 1, p. 77, 2021.
[4] P. Conti, C. D’Ovidio, C. Conti et al., “Progression in migraine: role of mast cells and pro-inflammatory and anti-inflammatory cytokines,” European Journal of Pharmacology, vol. 844, pp. 87–94, 2019.
[5] M. Yücel, D. Kotan, G. Gürol Çiftçi, I. H. Çiftçi, and H. I. Cikrilkar, “Serum levels of endocan, claudin-5 and cytokines in migraine,” European Review for Medical and Pharmacological Sciences, vol. 20, no. 5, pp. 930–936, 2016.
[6] A. Cayir, H. Cobanoglu, and M. Coskun, “Assessment of the genotoxic potential of a migraine-specific drug by comet and cytokinesis-block micronucleus assays,” Expert Opinion on Drug Metabolism & Toxicology, vol. 16, no. 5, pp. 441–446, 2020.
[7] T. Sprenger, M. Viana, and C. Tassorelli, “Current prophylactic medications for migraine and their potential mechanisms of action,” Neurotherapeutics, vol. 15, no. 2, pp. 313–323, 2018.
[8] D. Mohanty and S. Lippmann, “CGRP inhibitors for migraine,” Innovations in Clinical Neuroscience, vol. 17, no. 4–6, pp. 39–40, 2020.
[9] F. J. Erbguth, “From poison to remedy; the chequered history of botulinum toxin,” Journal of Neural Transmission, vol. 115, no. 4, pp. 559–565, 2008.
[10] W. J. Binder, M. F. Brin, A. Blitzer, L. D. Schoenrock, and J. M. Pogoda, “Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study,” Otologyngology-Head and Neck Surgery, vol. 123, no. 6, pp. 669–676, 2000.
[11] R. Burstein, A. M. Blumenfeld, S. D. Silberstein, A. Manack Adams, and M. F. Brin, “Mechanism of action of OnabotulinumtoxinA in chronic migraine: a narrative review,” Headache: The Journal of Head and Face Pain, vol. 60, no. 7, pp. 1259–1272, 2020.
[12] T. P. Do, J. Hvedstrup, and H. W. Schytz, “Botulinum toxin: a review of the mode of action in migraine,” Acta Neurologica Scandinavica, vol. 137, no. 5, pp. 442–451, 2018.
[13] D. W. Dodick, C. C. Turkel, R. E. DeGryse et al., “OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program,” Headache: The Journal of Head and Face Pain, vol. 50, no. 6, pp. 921–936, 2010.
[14] L. Bendtsen, S. Sacco, M. Ashina et al., “Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation,” The Journal of Headache and Pain, vol. 19, no. 1, pp. 91–108, 2018.
[15] National Institute for Health and Care Excellence, Botulinum Toxin Type a for the Prevention of Headaches in Adults with Chronic Migraine, National Institute for Health and Care Excellence, London, UK, 2012.
[16] N. Shaterian, R. Pakzad, S.-D. Fekri, F. Abdi, N. Shaterian, and M. Shojaee, “Labor pain in different dilatations of the cervix and apgar scores affected by aromatherapy: a systematic review and meta-analysis,” Reproductive Sciences (Thousand Oaks, Calif.), pp. 1–17, In press, 2021.
[17] A. J. Shuhendler, S. Lee, M. Sui et al., “Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials,” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol. 29, no. 7, pp. 784–791, 2009.
[18] N. Shaterian, F. Abdi, Z. A. Kashani, N. Shaterian, and M. Darvishmotavali, “Facemask and respirator in reducing the spread of respiratory viruses; a systematic review,” Archives of Academic Emergency Medicine, vol. 9, no. 1, p. e56, 2021.
[19] P. K. Winner, M. Kabbouche, M. Yonker, V. Wangsadipura, A. Lum, and M. F. Brin, “A randomized trial to evaluate onabotulinumtoxina for prevention of headaches in adolescents with chronic migraine,” Headache: The Journal of Head and Face Pain, vol. 60, no. 3, pp. 564–575, 2020.
[20] F. Ahmed, C. Gaul, J. García-Moncón, K. Sommer, and P. Martelletti, “Principal Investigators REPOSE (2019) an open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study,” The Journal of Headache and Pain, vol. 20, no. 1, p. 26, 2019.
[21] L. Tang, B. Bie, S.-E. Park, and D. Zhi, “Social media and outbreaks of emerging infectious diseases: a systematic review of literature,” American Journal of Infection Control, vol. 46, no. 9, pp. 962–972, 2018.
[22] L. Grazzi, “Onabotulinumtoxin a for chronic migraine with medication overuse: clinical results of a long-term treatment,” Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 38, no. 1, pp. 141–143, 2017.
[23] B. E. Demiryurek, D. H. Ertem, A. Tekin, M. Ceylan, Y. G. Aras, and B. D. Gungen, “Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine,” Neurological Sciences, vol. 37, no. 11, pp. 1779–1784, 2016.
[24] R. B. Lipton, N. L. Rosen, J. Ailani, R. E. DeGryse, P. J. Gillard, and S. F. Varon, "OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program," *Cephalalgia*, vol. 36, no. 9, pp. 899–908, 2016.

[25] M. Vikelis, A. A. Argyriou, E. V. Dermitzakis, K. C. Spingos, and D. D. Mitsikostas, "Onabotulinumtoxin-A treatment in Greek patients with chronic migraine," *The Journal of Headache and Pain*, vol. 17, no. 1, pp. 84–85, 2016.

[26] F. Ahmed, H. W. Zafar, A. Buture, and M. Khalil, "Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse," *SpringerPlus*, vol. 4, no. 1, pp. 1–8, 2015.

[27] G. P. Boudreau, B. Grosberg, P. McAllister, R. Lipton, and D. Buse, "Pharmacological onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety," *International Journal of General Medicine*, vol. 8, p. 79, 2015.

[28] R. Cady, I. Turner, K. Dexter, M. E. Beach, R. Cady, and P. Durham, "An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with OnabotulinumtoxinA in chronic migraine," *Headache: The Journal of Head and Face Pain*, vol. 54, no. 2, pp. 269–277, 2014.

[29] E. Cernuad-Morollón, C. Ramón, D. Larrosa, R. Alvarez, N. Riesco, and J. Pascual, "Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year?" *Cephalalgia*, vol. 35, no. 10, pp. 864–868, 2015.

[30] L. Holland, L. Monteiro, and A. Melo, "Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial," *Neurology International*, vol. 6, no. 4, p. 5133, 2014.

[31] S. K. Aurora, D. W. Dodick, H. C. Diener et al., "OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program," *Acta Neurologica Scandinavica*, vol. 129, no. 1, pp. 61–70, 2014.

[32] R. K. Cady, C. P. Schreiber, J. A. H. Porter, A. M. Blumenfeld, and K. U. Farmer, "A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine," *Headache: The Journal of Head and Face Pain*, vol. 51, no. 1, pp. 21–32, 2011.

[33] S. Chankrachang, A. Arayawichanont, N. Poungvarin et al., "Prophylactic botulinum type A toxin complex (dispot) for migraine without aura," *Headache: The Journal of Head and Face Pain*, vol. 51, no. 1, pp. 52–63, 2011.

[34] R. B. Lipton, S. F. Varon, B. Grosberg et al., "OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine," *Neurology*, vol. 77, no. 15, pp. 1465–1472, 2011.

[35] S. K. Aurora, P. Winner, M. C. Freeman et al., "OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program," *Headache: The Journal of Head and Face Pain*, vol. 51, no. 9, pp. 1358–1373, 2011.

[36] Õ. Õ. Akçay, "Does the efficacy of different doses of Botulinum neurotoxin in chronic migraine change in terms of age and sex?" *Gülhane Tip Dergisi*, vol. 62, no. 1, p. 51, 2020.

[37] K. Görür, H. Gür, O. İsmi, C. Özcan, and Y. Vayısıoğlu, "The effectiveness of propranolol, flunarizine, amitriptyline and botulinum toxin in vestibular migraine complaints and prophylaxis: a non-randomized controlled study," *Brazilian Journal of Otorhinolaryngology*, vol. 21, 2021.

[38] A. Oterino, C. Ramón, and J. Pascual, "Experience with onabotulinumtoxin A (BOTOX) in chronic refractory migraine: focus on severe attacks," *The Journal of Headache and Pain*, vol. 12, no. 2, pp. 235–238, 2011.

[39] M. Hou, J.-F. Xie, X.-P. Kong et al., "Acupoint injection of onabotulinumtoxin A for migraines," *Toxins*, vol. 7, no. 11, pp. 4442–4454, 2015.

[40] M. Alshalah, A. J. Al-Jawad, and H. H. J. Al-Jawad, "Effect of Botox (botulinum toxin) on pain management for patient suffering from temporomandibular joint disorder & migraine," *Annals of the Romanian Society for Cell Biology*, vol. 25, no. 5, pp. 2811–2815, 2021.

[41] S. Shah, M.-D. Calderon, W. D. Wu, J. Grant, and J. Rinehart, "Onabotulinumtoxin A (botox) for Prophylactic treatment of pediatric migraine: a retrospective longitudinal analysis," *Journal of Child Neurology*, vol. 33, no. 9, pp. 580–586, 2018.

[42] S. Shah, M.-D. Calderon, N. Crain, J. Pham, and J. Rinehart, "Effectiveness of onabotulinumtoxinA (BOTOX) in pediatric patients experiencing migraines: a randomized, double-blinded, placebo-controlled crossover study in the pediatric pain population," *Regional Anesthesia & Pain Medicine*, vol. 46, no. 1, pp. 41–48, 2021.

[43] T. Sycha, G. Kranz, E. Auff, and P. Schneider, "Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature," *Journal of Neurology*, vol. 251, no. 1, p. 1, 2004.

[44] V. K. Gupta, "Botulinum toxin-A treatment for migraine? A systematic review," *Pain Medicine*, vol. 7, no. 5, pp. 386–394, 2006.

[45] M. Linde, K. Hagen, and L. J. Stovner, "Botulinum toxin treatment of secondary headaches and cranial neuralgias: a review of evidence," *Acta Neurologica Scandinavica*, vol. 124, no. 591, pp. 50–55, 2011.

[46] H. Mmehe, A. M. Fenech Magrin, S. Myers, and A. M. Ghanem, "A critical review of botulinum toxin type A in the prophylactic treatment of chronic migraine in adults," *Aesthetic Surgery Journal*, vol. 39, no. 8, pp. 898–907, 2019.

[47] C. P. Herd, C. L. Tomlinson, C. Rick et al., "Choochy systematic review and meta-analysis of botulinum toxin for the prevention of migraine," *BMJ Open*, vol. 9, no. 7, Article ID e027953, 2019.

[48] B. Shen and L. Wang, "Impact of the botulinum-A toxin on prevention of adult migraine disorders," *Journal of Integrative Neuroscience*, vol. 19, no. 1, pp. 201–208, 2020.

[49] L. M. Loeb, R. P. Amorim, M. d. G. N. Mazzacoratti, F. A. Scorza, and M. F. P. Peres, "Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison," *Arquivos de neuro-psiquiatria*, vol. 76, no. 10, pp. 663–667, 2018.

[50] F. Cheng and F. Ahmed, "OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation," *Expert Opinion on Drug Safety*, vol. 20, no. 11, pp. 1–15, 2021.

[51] F. Ahmed, A. Buture, T. Tanvir, and M. Khalil, "Long term outcome for onabotulinumtoxinA (Botox) therapy in chronic migraine: a 2-year prospective follow-up audit of patients attending the Hull (UK) migraine clinic," *Cephalalgia Reports*, vol. 4, Article ID 251581632098544, 2021.

[52] A. A. Argyriou, D.-D. Mitsikostas, E. Mantovani, M. Vikelis, and S. Tamburin, "Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders,"
[53] B. Naderinabi, A. Saberi, M. Hashemi et al., “Acupuncture and botulinum toxin A injection in the treatment of chronic migraine: a randomized controlled study,” Caspian Journal of Internal Medicine, vol. 8, no. 3, pp. 196–204, 2017.

[54] O. Affatato, T. C. Moulin, C. Pisanu, V. S. Babasieva, M. Russo, and E. I. Aydinlar, “High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis,” Journal of Translational Medicine, vol. 19, no. 1, pp. 1–11, 2021.

[55] G. Bandoli, R. J. Baer, D. Gano, L. J. Pawlowski, and C. Chambers, “Migraines during pregnancy and the risk of maternal stroke,” JAMA Neurology, vol. 77, no. 9, pp. 1177–1179, 2020.

[56] R. Burch, “Epidemiology and treatment of menstrual migraine and migraine during pregnancy and lactation: a narrative review,” Headache: The Journal of Head and Face Pain, vol. 60, no. 1, pp. 200–216, 2020.

[57] A. R. Schoenbrunner, I. Khansa, and J. E. Janis, “Cost-effectiveness of long-term, targeted onabotulinumtoxinA versus peripheral trigger site deactivation surgery for the treatment of refractory migraine headaches,” Plastic & Reconstructive Surgery, vol. 145, no. 2, pp. 401e–406e, 2020.